Evaluation of the Effectiveness of the Iralvex Gel on the Recurrent Aphthous Stomatitis Management (original) (raw)
Related papers
The Efficacy of Hyaluronic Acid Gel in Pain Control of Recurrent Aphthous Stomatitis
This study was conducted to evaluate the efficacy of topical hyaluronic acid gel (HA) and compared with triamcinolone acetonide pomad (TA) in the treatment and pain control of RAS. A total of 57 patients with a history of RAS and currently suffering from oral ulcer were selected from patients referred to clinic. The subjects randomly divided into two groups; one group have received HA gel (Aftamed ® Oral gel, AktiFarma. Istanbul, Turkey) the other group conceived TA pomade, (Kenacort-A Orabase ® Pomade, 0,1% Triamsinolon acetonide, Bristol-Myers Squibb Ilacları Inc. Istanbul, Turkey). All patients were instructed to apply the agents to the ulcer 4 times per day for 7 days (day 0 to day 6). To evaluate pain level, a visual analog scale (VAS) was used. Although there was no statistical difference between two groups by means of mean ulcer VAS scores (8.57±1.05 in HA group and 8.59±1.08 in TA group) at day 0, significant differences were found at day 4 (VAS score=4.88±0.83 in HA group and 5.82±1.07 in TA group) and day 7 (VAS score=2.30±0.90 in HA group and 3.07±0.97 in TA group). The ulcer pain score (VAS) of two groups decreased within time however, the pain score in HA group was statistically lower than that of the TA groups at day 4 and 7 (p<0.05). HA gel reduced the painfull symptoms of RAS when compared with TA pomad. These outcomes suggest that HA gel can be effectively used for pain control in RAS treatment.
Practical aspects of management of recurrent aphthous stomatitis
Journal of The European Academy of Dermatology and Venereology, 2007
Treatment of recurrent aphthous stomatitis (RAS) remains, to date, empirical and non-specific. The main goals of therapy are to minimize pain and functional disabilities as well as decrease inflammatory reactions and frequency of recurrences. Locally, symptomatically acting modalities are the standard treatment in simple cases of RAS. Examples include topical anaesthetics and analgesics, antiseptic and anti-phlogistic preparations, topical steroids as cream, paste or lotions, antacids like sucralfate, chemically stable tetracycline suspension, medicated toothpaste containing the enzymes amyloglucosidase and glucoseoxidase in addition to the well-known silver nitrate application. Dietary management supports the treatment. In more severe cases, topical therapies are again very useful in decreasing the healing time but fail to decrease the interval between attacks. Systemic immunomodulatory agents, like colchicine, pentoxifylline, prednisolone, dapsone, levamisol, thalidomide, azathioprine, methotrexate, cyclosporin A, interferon alpha and tumour necrosis factor (TNF) antagonists, are helpful in resistant cases of major RAS or aphthosis with systemic involvement.
International Journal of Contemporary Medical Research [IJCMR]
Introduction: Recurrent aphthous stomatitis (RAS) is a common condition of the mucosa of oral cavity characterized by recurrent attacks of small, round or oval, painful affecting 5-25% of the general population and rarely involves genital region. These lesions occur most commonly on the nonkeratinized epithelium of oral cavity and ulcers heal within a period of 10-14 days with characteristic feature of pain causing difficulty on chewing, swallowing, and/or speaking. So, the purpose of present study was to evaluate the effectiveness of Amlexanox 5% and Triamcinolone 0.1% for the treatment of recurrent aphthous ulcers. Material and Methods: This double-blinded randomized clinical study done in the Department of Oral Medicine And Radiology, Government dental college Srinagar includes 36 patients suffering from recurrent aphthous ulcers aged between 25 and 55 years old and, having minor aphthous ulcers not more than 48 hours old. Group-1 was administered with Triamcinolone 0.1% (Kenocort 0.1% oral paste, Abbort Laboratories Chicago USA), while the group-2 was administered with Amlexanox 5% (Lexanox 5% oral paste, macleods Pharmaceuticals India). The patients used these pastes four times daily for 7 days. The patients were followed at days 0, 3, 5 and 7 and scores were assessed using visual analog scale.
Current concepts in the treatment of recurrent aphthous stomatitis
Skin therapy letter, 2008
The treatment of recurrent aphthous stomatitis (RAS) still remains nonspecific and is based primarily on empirical data. The goals of therapy include the management of pain and functional impairment by suppressing inflammatory responses, as well as reducing the frequency of recurrences or avoiding the onset of new aphthae. For common forms of RAS, standard topical treatment options that provide symptomatic relief include analgesics, anesthetics, antiseptics, anti-inflammatory agents, steroids, sucralfate, tetracycline suspension, and silver nitrate. Dietary modifications may also support therapeutic measures. In resistant cases of benign aphthosis or aphthosis with systemic involvement, appropriate systemic treatment can be selected from a wide spectrum of immunomodulators that include colchicine, prednisolone, cyclosporine A, interferon-a, tumor necrosis factor-a antagonists, antimetabolites, and alkylating agents.
Challenges in Diagnosis and Treatment of Recurrent Aphthous Stomatitis
Journal of Medical and Dental Practice
Modern medicine and advanced research nowadays allow clinicians to correctly diagnose and treat recurrent aphthous stomatitis, which can impact affected individuals functionally, psychosocially and economically. This review has been designed to investigate the diagnosis and treatment options of RAS based on the etiopathogenesis of the aphthous ulcers. The success of treatment depends on the timely and correct diagnosis of the lesions. Although pinpointing a precise etiological factor is difficult, various plausible of them are discussed in this review. Treatment modalities allow efficient and effective palliative care, along with rapid healing of affected mucosa. Further research should be made to isolate the aetiology of RAS for every case and the efficiency of conventional and unconventional treatment options, and possible side effects of such.
International Journal of Preventive and Clinical Dental Research
Background: Although there are many drugs which are used for topical therapy in recurrent aphthous stomatitis (RAS) patients, there are few clinical trials that have used tetracycline and amlexanox. Aim and Objectives: To evaluated the therapeutic efficacy of topical tetracycline and amlexanox. Materials and Methods: Here in this study we divided the RAS patients into two groups in each group alternative selection was done. Patients of 1st Group received topical application of tetracycline crushed tablets with denture adhesive and few drops of saline solution on each alternative day visit. Same as Group 2nd subject received amlexanox. Treatment response was assessed by measuring pain reduction, photographic record, ulcer duration, and adhesive retention time. Results: Amlexanox oral paste show more efficacy in comparision of topical tetracycline in the treatment of recurrent minor aphthous ulcers. Conculsion: Amlexanox is more effective in comparison of tetracycline.
Cureus
Background The oral condition known as recurrent aphthous ulceration (RAU) or recurrent aphthous stomatitis (RAS) is very prevalent. Its etiopathogenesis is unknown; hence, symptomatic therapy is all that can be offered if it manifests clinically. Lesion care aims to minimize discomfort and the frequency of relapses by bringing active illness under local control in the affected area. The current treatment options that may have negative side effects include the use of topical and systemic steroids, antibiotics, cauterization, and laser therapy. Objectives and Importance This study aimed to compare the efficiency of HiOra SG gel with triamcinolone acetonide gel in the management of RAS. Materials and Methods Fifty individuals with RAS were recruited for the trial and randomly assigned to either group I (HiOra SG gel) or group II (0.1% triamcinolone acetonide ointment; Oraways). After each meal for a total of 10 days, those with mouth ulcers were instructed to topically administer the drugs. The clinical data were analyzed by comparing the ulcer severity scores from the first, fifth, and 10th days. Results There was a statistically significant (p = 0.001) reduction in reported pain, pain duration, and overall ulcer severity across all groups. After therapy, however, neither the HiOra gel group nor the triamcinolone group showed any discernible improvement over the other. Conclusion The present study's findings corroborate the efficacy of HiOra SG gel in the treatment of RAS when compared to triamcinolone acetonide gel (0.1%). In this trial, no patients had any negative reactions to HiOra SG gel. In the future, further studies are needed with larger samples to prove its benefits.
Therapeutic effect of proaftol in treatment of recurrent aphthous stomatitis
PRILOZI, 2014
Recurrent aphthous stomatitis (RAS) is a quite frequent, painful, ulcerative disease that affects the lining of the oral cavity and has an unknown etiology. The aim of this article is to examine the impact of the medication proaftol on epithelization speed and severity of pain in patients with RAS. In this randomized, double-blind, placebo-controlled study respondents were divided into two groups where one group was treated with proaftol spray and the other with a placebo. Aphthae considered for treatment had a diameter of 5-6 mm. The participants were given instruction on the use of the spray, two sprayings on the place of the aphtae 3-4 times a day. We examined two parameters in the symptomatology of RAS-lesion size (mm) and pain intensity (noted on four subjective levels: 0-no pain, 1-discomfort, 2-moderate pain, 3-severe pain). These parameters were noted on the baseline, the third, the fifth and the eighth days of examination.
Recurrent Aphthous Stomatitis: Towards Evidence-Based Treatment?
Current Oral Health Reports, 2015
Recurrent aphthous stomatitis is one of the most common oral mucosal diseases seen by dental professionals, and yet its etiology remains unclear, and its management based on less than robust evidence. The literature remains confused because of the lack of clarity in diagnosis and the lack of a standardized ulcer severity scoring system and agreed outcome measures. However, recent literature is encouraging in meeting these aims. There is agreement that RAS is a localized mucosal disease not secondary to systemic disease and therefore distinguishable from over forty other types of oral ulcers. Disease severity scores have been introduced and outcome measures have become more standardized. RAS appears to be an auto-immune disease directed at epitopes of heat shock proteins while most recent work on etiology has focused on cytokines and genetics. Pro-inflammatory cytokines including TNFa and IL-6 and IL-17 are raised in RAS and TNF inhibitors can inhibit episodes of ulceration. Many local anti-inflammatory agents will help ulcers heal, and local steroids remain the treatment of choice. Some systemic drugs have evidence based data indicating efficacy at preventing new ulcers including colchicine, prednisolone, thalidomide, pentoxyfilline and dapsone. The field would benefit from further trials combining local and systemic therapy using defined outcome measures.